Combined Intranasal Nanoemulsion and RIG‑I
Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity
to Influenza Virus
Version 2 2020-06-17, 19:11
Version 1 2020-06-15, 14:08
Posted on 2020-06-17 - 19:11
Current
influenza virus vaccines are focused on humoral immunity
and are limited by the short duration of protection, narrow cross-strain
efficacy, and suboptimal immunogenicity. Here, we combined two chemically
and biologically distinct adjuvants, an oil-in-water nanoemulsion
(NE) and RNA-based agonists of RIG-I, to determine whether the diverse
mechanisms of these adjuvants could lead to improved immunogenicity
and breadth of protection against the influenza virus. NE activates
TLRs, stimulates immunogenic apoptosis, and enhances cellular antigen
uptake, leading to a balanced TH1/TH2/TH17 response when administered intranasally. RIG-I agonists
included RNAs derived from Sendai and influenza viral defective interfering
RNAs (IVT DI, 3php, respectively) and RIG-I/TLR3 agonist, poly(I:C)
(pIC), which induce IFN-Is and TH1-polarized responses.
NE/RNA combined adjuvants potentially allow for costimulation of multiple
innate immune receptor pathways, more closely mimicking patterns of
activation occurring during natural viral infection. Mice intranasally
immunized with inactivated A/Puerto Rico/8/1934 (H1N1) (PR/8) adjuvanted
with NE/IVT DI or NE/3php (but not NE/pIC) showed synergistic enhancement
of systemic PR/8-specific IgG with significantly greater avidity and
virus neutralization activity than the individual adjuvants. Notably,
NE/IVT DI induced protective neutralizing titers after a single immunization.
Hemagglutinin stem-specific antibodies were also improved, allowing
recognition of heterologous and heterosubtypic hemagglutinins. All
NE/RNAs elicited substantial PR/8-specific sIgA. Finally, a unique
cellular response with enhanced TH1/TH17 immunity
was induced with the NE/RNAs. These results demonstrate that the enhanced
immunogenicity of the adjuvant combinations was synergistic and not
simply additive, highlighting the potential value of a combined adjuvant
approach for improving the efficacy of vaccination against the influenza
virus.
CITE THIS COLLECTION
DataCite
3 Biotech
3D Printing in Medicine
3D Research
3D-Printed Materials and Systems
4OR
AAPG Bulletin
AAPS Open
AAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)
Academic Medicine
Academic Pediatrics
Academic Psychiatry
Academic Questions
Academy of Management Discoveries
Academy of Management Journal
Academy of Management Learning and Education
Academy of Management Perspectives
Academy of Management Proceedings
Academy of Management Review
Wong, Pamela T.; Goff, Peter H.; Sun, Rachel J.; Ruge, Matthew J.; Ermler, Megan E.; Sebring, Alyssa; et al. (2020). Combined Intranasal Nanoemulsion and RIG‑I
Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity
to Influenza Virus. ACS Publications. Collection. https://doi.org/10.1021/acs.molpharmaceut.0c00315
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics
Read the peer-reviewed publication
AUTHORS (11)
PW
Pamela T. Wong
PG
Peter H. Goff
RS
Rachel J. Sun
MR
Matthew J. Ruge
ME
Megan E. Ermler
AS
Alyssa Sebring
JO
Jessica J. O’Konek
JL
Jeffrey J. Landers
KJ
Katarzyna W. Janczak
WS
Weina Sun
JB
James R. Baker